{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:29:53Z","timestamp":1789622993945,"version":"build-2803163510"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.intimp.2023.110214","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T16:48:45Z","timestamp":1682786925000},"page":"110214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["The interactions of docetaxel with tumor microenvironment"],"prefix":"10.1016","volume":"119","author":[{"given":"Reena","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa M.","family":"Kadhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abduladheem","family":"Turki Jalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Qasim Alasheqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alsaikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurkhan","family":"Khalimovna Mukhamedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Alexis Ram\u00edrez-Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanko","family":"Hassan Jawhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpamala","family":"Ramaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110214_b0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/joim.13139","article-title":"Cancer survival statistics for patients and healthcare professionals - a tutorial of real-world data analysis","volume":"289","author":"Eloranta","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.intimp.2023.110214_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1440-1681.13725","article-title":"Apigenin in cancer therapy: Prevention of genomic instability and anticancer mechanisms","volume":"50","author":"Moslehi","year":"2023","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.intimp.2023.110214_b0015","first-page":"1","article-title":"Cardiac inflammation and fibrosis following chemo\/radiation therapy: mechanisms and therapeutic agents","author":"Yang","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.intimp.2023.110214_b0020","doi-asserted-by":"crossref","unstructured":"P. Amini, R. Moazamiyanfar, M.S. Dakkali, A. Khani, E. Jafarzadeh, K. Mouludi, E. Khodamoradi, R. Johari, S. Taeb, M. Najafi, Resveratrol in cancer therapy; from stimulation of genomic stability to adjuvant cancer therapy; A comprehensive review. Curr Top Med Chem, 2022.","DOI":"10.2174\/1568026623666221014152759"},{"key":"10.1016\/j.intimp.2023.110214_b0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1568009622666211224154952","article-title":"Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy","volume":"22","author":"Taeb","year":"2022","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.intimp.2023.110214_b0030","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/med.21765","article-title":"Understanding the tumor microenvironment for effective immunotherapy","volume":"41","author":"Sadeghi Rad","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.intimp.2023.110214_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106761","article-title":"Damage-associated molecular patterns in tumor radiotherapy","volume":"86","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.110214_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106663","article-title":"Abscopal effect in radioimmunotherapy","volume":"85","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.110214_b0045","doi-asserted-by":"crossref","unstructured":"J. \u0160kubn\u00edk, V. Pavl\u00ed\u010dkov\u00e1, T. Ruml, S. Rimpelov\u00e1, Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy. Plants (Basel), 2021; 10.","DOI":"10.3390\/plants10030569"},{"key":"10.1016\/j.intimp.2023.110214_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108555","article-title":"The interactions of paclitaxel with tumour microenvironment","volume":"105","author":"Yu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.110214_b0055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.trecan.2020.02.004","article-title":"Towards the microbial production of plant-derived anticancer drugs","volume":"6","author":"Courdavault","year":"2020","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0060","doi-asserted-by":"crossref","first-page":"e1900631","DOI":"10.1002\/cbdv.201900631","article-title":"Synthesis of Taxol and Docetaxel by Using 10-Deacetyl-7-xylosyltaxanes","volume":"17","author":"Xue","year":"2020","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.intimp.2023.110214_b0065","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijbiomac.2019.12.145","article-title":"Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics","volume":"145","author":"Ashrafizadeh","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.intimp.2023.110214_b0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000506693","article-title":"Docetaxel rechallenge in patients with metastatic prostate cancer: a comprehensive review","volume":"43","author":"Assi","year":"2020","journal-title":"Oncology Research and Treatment"},{"key":"10.1016\/j.intimp.2023.110214_b0075","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(01)90148-4","article-title":"Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer","volume":"28","author":"Pienta","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.intimp.2023.110214_b0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1025436307913","article-title":"The mechanism of action of docetaxel (Taxotere\u00ae) in xenograft models is not limited to bcl-2 phosphorylation","volume":"21","author":"Kraus","year":"2003","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.intimp.2023.110214_b0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/138161210789941801","article-title":"Mechanisms of drug-induced mitotic catastrophe in cancer cells","volume":"16","author":"Portugal","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.intimp.2023.110214_b0095","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1021\/acs.jmedchem.1c00100","article-title":"Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy","volume":"64","author":"Shuai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2023.110214_b0100","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2174\/1389450123666220705123315","article-title":"Redox Interactions in Chemo\/Radiation Therapy-induced Lung Toxicity; Mechanisms and Therapy Perspectives","volume":"23","author":"Lai","year":"2022","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.intimp.2023.110214_b0105","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s11064-007-9577-5","article-title":"A calcium influx pathway regulated separately by oxidative stress and ADP-Ribose in TRPM2 channels: single channel events","volume":"33","author":"Naziro\u011flu","year":"2008","journal-title":"Neurochem Res"},{"key":"10.1016\/j.intimp.2023.110214_b0110","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s12640-019-0009-5","article-title":"Selenium Enhances the Apoptotic Efficacy of Docetaxel Through Activation of TRPM2 Channel in DBTRG Glioblastoma Cells","volume":"35","author":"Ertilav","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.intimp.2023.110214_b0115","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ijrobp.2016.07.002","article-title":"The Involvement of Mitochondrial Membrane Potential in Cross-Resistance Between Radiation and Docetaxel","volume":"96","author":"Kuwahara","year":"2016","journal-title":"Int. J. Radiat. Oncology*Biology*Physics"},{"key":"10.1016\/j.intimp.2023.110214_b0120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pros.22583","article-title":"Functional p53 determines docetaxel sensitivity in prostate cancer cells","volume":"73","author":"Liu","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.intimp.2023.110214_b0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10495-022-01721-4","article-title":"Nobiletin as an inducer of programmed cell death in cancer: a review","volume":"27","author":"Huang","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2023.110214_b0130","first-page":"667","article-title":"Involvement of NF-\u03baB and mitochondrial pathways in docetaxel-induced apoptosis of human oral squamous cell carcinoma","volume":"15","author":"Taniguchi","year":"2005","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.intimp.2023.110214_b0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2018.04.017","article-title":"Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer","volume":"427","author":"Singh","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2023.110214_b0140","doi-asserted-by":"crossref","first-page":"15061","DOI":"10.1038\/cddiscovery.2015.61","article-title":"Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2\u2013Akt axis","volume":"1","author":"Vinod","year":"2015","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.intimp.2023.110214_b0145","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-11-2088","article-title":"GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In VivoGDC-0941 Enhances Docetaxel Antitumor Activity","volume":"18","author":"Wallin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110214_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.05.076","article-title":"Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance","volume":"231","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2023.110214_b0155","doi-asserted-by":"crossref","first-page":"e22708","DOI":"10.1002\/jbt.22708","article-title":"Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer","author":"Mortezaee","year":"2021","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.intimp.2023.110214_b0160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12079-021-00648-w","article-title":"Targeting of the tumor immune microenvironment by metformin","volume":"16","author":"Wu","year":"2022","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.intimp.2023.110214_b0165","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3390\/biology11060929","article-title":"Tumor Microenvironment\u2014A Short Review of Cellular and Interaction Diversity","volume":"11","author":"Bo\u017cyk","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.intimp.2023.110214_b0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2023.110214_b0175","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.3390\/cancers12123650","article-title":"TGF-\u03b2 Mediated Immune Evasion in Cancer\u2014Spotlight on Cancer-Associated Fibroblasts","volume":"12","author":"Ghahremanifard","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2023.110214_b0180","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5368","article-title":"Crosstalk between cancer and different cancer stroma subtypes promotes the infiltration of tumor-associated macrophages into the tumor microenvironment of oral squamous cell carcinoma","volume":"60","author":"Shan","year":"2022","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0185","first-page":"71","article-title":"Endothelial cells in the tumor microenvironment","author":"Sobierajska","year":"2020","journal-title":"Tumor Microenvironment"},{"key":"10.1016\/j.intimp.2023.110214_b0190","first-page":"882","article-title":"Profiling of tumor microenvironment components identifies five stroma-related genes with prognostic implications in colorectal cancer","volume":"37","author":"Liu","year":"2022","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.intimp.2023.110214_b0195","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110214_b0200","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cyto.2019.02.001","article-title":"The role of cytokines in the regulation of NK cells in the tumor environment","volume":"117","author":"Konjevi\u0107","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2023.110214_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156081","article-title":"The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance","volume":"161","author":"Canar","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2023.110214_b0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.canlet.2021.02.013","article-title":"The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells","volume":"506","author":"Cheng","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2023.110214_b0215","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-021-01448-x","article-title":"Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934\/SHP2 axis in NSCLC","volume":"20","author":"Chen","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0220","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3892\/ijo.2011.1292","article-title":"Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer","volume":"40","author":"Wenner","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0225","first-page":"599","article-title":"Enhancement of tumor radioresponse by docetaxel: Involvement of immune system","volume":"18","author":"Mason","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0230","doi-asserted-by":"crossref","first-page":"e1074378","DOI":"10.1080\/2162402X.2015.1074378","article-title":"Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors","volume":"5","author":"Acebes-Huerta","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.intimp.2023.110214_b0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.18632\/oncotarget.6353","article-title":"Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition","volume":"7","author":"Di Modica","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2023.110214_b0240","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid\u00ae (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2023.110214_b0245","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/pros.23988","article-title":"Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals","volume":"80","author":"Tang","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.intimp.2023.110214_b0250","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The Intersection between Tumor Angiogenesis and Immune Suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.intimp.2023.110214_b0255","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2023.110214_b0260","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jtho.2019.03.028","article-title":"Immune cell infiltration may be a key determinant of long-term survival in small cell lung cancer","volume":"14","author":"Muppa","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0265","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","article-title":"Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement","volume":"14","author":"Garnett","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.intimp.2023.110214_b0270","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0284","article-title":"Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer","volume":"26","author":"Guan","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0275","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/biom9080339","article-title":"Acute vs. chronic vs. cyclic hypoxia: their differential dynamics, molecular mechanisms, and effects on tumor progression","volume":"9","author":"Saxena","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2023.110214_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.145796","article-title":"Up-down regulation of HIF-1\u03b1 in cancer progression","volume":"798","author":"Rashid","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.intimp.2023.110214_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40675-017-0062-7","article-title":"Hypoxia-Inducible Factors and Cancer","volume":"3","author":"Jun","year":"2017","journal-title":"Curr Sleep Med Rep"},{"key":"10.1016\/j.intimp.2023.110214_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment","volume":"21","author":"Emami Nejad","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2023.110214_b0295","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0300","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.urolonc.2010.08.015","article-title":"Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells","volume":"30","author":"Forde","year":"2012","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"10.1016\/j.intimp.2023.110214_b0305","doi-asserted-by":"crossref","first-page":"27382","DOI":"10.1038\/srep27382","article-title":"Docetaxel induced-JNK2\/PHD1 signaling pathway increases degradation of HIF-1\u03b1 and causes cancer cell death under hypoxia","volume":"6","author":"Oh","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.110214_b0310","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1158\/0008-5472.CAN-04-4095","article-title":"Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function","volume":"65","author":"Escuin","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.intimp.2023.110214_b0315","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4174232","article-title":"Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial-Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1\u03b1","volume":"2018","author":"Qian","year":"2018","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.intimp.2023.110214_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100821","article-title":"Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1\u03b1\/miR-494\/Survivin signaling pathway","volume":"32","author":"Li","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2023.110214_b0325","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.3390\/cancers13184573","article-title":"Immune Checkpoints in Cancers: From Signaling to the Clinic","volume":"13","author":"Pisibon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2023.110214_b0330","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3390\/cancers11111756","article-title":"Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer","volume":"11","author":"Marhelava","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2023.110214_b0335","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/gene.2013.57","article-title":"Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation","volume":"15","author":"Chan","year":"2014","journal-title":"Genes Immun."},{"key":"10.1016\/j.intimp.2023.110214_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110214_b0345","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.3390\/ijms20215347","article-title":"PD-L1\/PD-1 axis in glioblastoma multiforme","volume":"20","author":"Litak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.110214_b0350","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/cancers13020164","article-title":"PD-L1\/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression","volume":"13","author":"Costa","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2023.110214_b0355","article-title":"Boosting anti-tumour immunity using adjuvant apigenin","author":"Huang","year":"2022","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.intimp.2023.110214_b0360","doi-asserted-by":"crossref","first-page":"e000236","DOI":"10.1136\/esmoopen-2017-000236","article-title":"Anti-PD-1\/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials","volume":"2","author":"Ramos-Esquivel","year":"2017","journal-title":"ESMO open"},{"key":"10.1016\/j.intimp.2023.110214_b0365","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12032-021-01555-1","article-title":"Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions","volume":"38","author":"Maulhardt","year":"2021","journal-title":"Med. Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0370","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1186\/s12885-022-10045-0","article-title":"Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2022.06.003","article-title":"A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non\u2013Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1\/PD-L1 Blockade","volume":"23","author":"Osta","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0380","article-title":"A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non\u2013small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029","volume":"n\/a","author":"Salous","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0385","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1158\/1078-0432.CCR-22-1687","article-title":"A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Na\u00efve Non-Small Cell Lung Cancer: TORG1630","volume":"28","author":"Taniguchi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110214_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106807","article-title":"The interactions and communications in tumor resistance to radiotherapy: Therapy perspectives","volume":"87","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.110214_b0395","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10495-022-01750-z","article-title":"Mechanisms of cancer cell death induction by paclitaxel: an updated review","volume":"27","author":"Zhao","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2023.110214_b0400","doi-asserted-by":"crossref","first-page":"02168","DOI":"10.3389\/fimmu.2020.02168","article-title":"CXCR4 inhibition counteracts immunosuppressive properties of metastatic NSCLC stem cells","volume":"11","author":"Fortunato","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110214_b0405","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1593\/neo.12324","article-title":"CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy","volume":"14","author":"Domanska","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2023.110214_b0410","doi-asserted-by":"crossref","first-page":"11490","DOI":"10.18632\/oncotarget.2571","article-title":"CXCL12\/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1","volume":"5","author":"Bhardwaj","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2023.110214_b0415","doi-asserted-by":"crossref","first-page":"25903","DOI":"10.1074\/jbc.M603414200","article-title":"Cross-talk between Epidermal Growth Factor Receptor and Hypoxia-inducible Factor-1\u03b1 Signal Pathways Increases Resistance to Apoptosis by Up-regulating Survivin Gene Expression *","volume":"281","author":"Peng","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2023.110214_b0420","doi-asserted-by":"crossref","first-page":"4174232","DOI":"10.1155\/2018\/4174232","article-title":"Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial-Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1<i>\u03b1<\/i>","volume":"2018","author":"Qian","year":"2018","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.intimp.2023.110214_b0425","doi-asserted-by":"crossref","first-page":"80943","DOI":"10.18632\/oncotarget.13115","article-title":"Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1\u03b1 and sphingosine kinase 1","volume":"7","author":"Alshaker","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2023.110214_b0430","first-page":"B61","article-title":"Nitroglycerin treatment may increase response to docetaxel and carboplatin regimen via inhibitions of hypoxia-inducible factor-1 pathway and P-glycoprotein in patients with lung adenocarcinoma","volume":"12","author":"Yasuda","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110214_b0435","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.imbio.2019.03.002","article-title":"Depletion of tumor-associated macrophages enhances the anti-tumor effect of docetaxel in a murine epithelial ovarian cancer","volume":"224","author":"Lu","year":"2019","journal-title":"Immunobiology"},{"key":"10.1016\/j.intimp.2023.110214_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.12.004","article-title":"Enhancing solid tumor therapy with sequential delivery of dexamethasone and docetaxel engineered in a single carrier to overcome stromal resistance to drug delivery","volume":"294","author":"Zhang","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2023.110214_b0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-67904-8","article-title":"Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer","volume":"10","author":"Fujiwara","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.110214_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111824","article-title":"New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities","volume":"141","author":"Ashrafizadeh","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2023.110214_b0455","doi-asserted-by":"crossref","first-page":"e70960","DOI":"10.1371\/journal.pone.0070960","article-title":"Candidate Markers That Associate with Chemotherapy Resistance in Breast Cancer through the Study on Taxotere-Induced Damage to Tumor Microenvironment and Gene Expression Profiling of Carcinoma-Associated Fibroblasts (CAFs)","volume":"8","author":"Rong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.110214_b0460","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.2147\/IJN.S171224","article-title":"Prior anti-CAFs break down the CAFs barrier and improve accumulation of docetaxel micelles in tumor","volume":"13","author":"Pang","year":"2018","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.intimp.2023.110214_b0465","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jconrel.2015.03.023","article-title":"Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle","volume":"206","author":"Ernsting","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2023.110214_b0470","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jtbi.2018.11.018","article-title":"Mathematical modeling in scheduling cancer treatment with combination of VEGF inhibitor and chemotherapy drugs","volume":"462","author":"Lai","year":"2019","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.intimp.2023.110214_b0475","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.3390\/cancers12092382","article-title":"Angiogenesis inhibition in prostate cancer: An update","volume":"12","author":"Sarkar","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2023.110214_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.01.025","article-title":"Multicenter real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with PD-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)","author":"Nakamura","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0485","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s10637-022-01214-w","article-title":"Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study","volume":"40","author":"Kawachi","year":"2022","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.intimp.2023.110214_b0490","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2006.08.002","article-title":"Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer","volume":"33","author":"Ellis","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.intimp.2023.110214_b0495","doi-asserted-by":"crossref","first-page":"459","DOI":"10.21037\/tlcr.2020.03.29","article-title":"Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged \u226575 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323","volume":"9","author":"Kozuki","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.intimp.2023.110214_b0500","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1177\/0300060519852202","article-title":"A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer","volume":"47","author":"Shimizu","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.intimp.2023.110214_b0505","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0510","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919864236","article-title":"Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08\u201310 trial","volume":"11","author":"Gullo","year":"2019","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1016\/j.intimp.2023.110214_b0515","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00280-020-04201-1","article-title":"A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma","volume":"87","author":"Murray Stewart","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110214_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112039","article-title":"Oral administration co-delivery nanoparticles of docetaxel and bevacizumab for improving intestinal absorption and enhancing anticancer activity","volume":"124","author":"Feng","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.intimp.2023.110214_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121682","article-title":"Glioblastoma multiforme targeted delivery of docetaxel using bevacizumab-modified nanostructured lipid carriers impair in vitro cell growth and in vivo tumor progression","volume":"618","author":"Di Filippo","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.intimp.2023.110214_b0530","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14737140.2016.1241147","article-title":"The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer","volume":"16","author":"Paulus","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.intimp.2023.110214_b0535","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(19)30668-0","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial","volume":"21","author":"Petrylak","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0540","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0140-6736(17)32365-6","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial","volume":"390","author":"Petrylak","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.110214_b0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-020-00752-w","article-title":"Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)","volume":"20","author":"Necchi","year":"2020","journal-title":"BMC Urol."},{"key":"10.1016\/j.intimp.2023.110214_b0550","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1111\/bcp.15233","article-title":"Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy","volume":"88","author":"de Wit","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110214_b0555","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2020.04.021","article-title":"Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1\/PD-L1 treatment","volume":"144","author":"Tozuka","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0560","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00432-007-0247-4","article-title":"Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent\u00ae) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer","volume":"134","author":"Gu\u00e9rin","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0565","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/annonc\/mdp323","article-title":"Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy","volume":"21","author":"Sonpavde","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0570","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/bjc.2012.100","article-title":"Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum","volume":"106","author":"Yi","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2023.110214_b0575","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","article-title":"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.intimp.2023.110214_b0580","doi-asserted-by":"crossref","unstructured":"Ang YL, Ho GF, Soo RA, Sundar R, Tan SH, Yong WP, Ow SG, Lim JS, Chong WQ, Soe PP. A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC cancer, 2020; 20: 1-10.","DOI":"10.1186\/s12885-020-07616-4"},{"key":"10.1016\/j.intimp.2023.110214_b0585","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2019.02.002","article-title":"Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study","volume":"45","author":"Mavratzas","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.intimp.2023.110214_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2020.101959","article-title":"Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer","volume":"60","author":"Imran","year":"2020","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.intimp.2023.110214_b0595","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ijbiomac.2019.03.241","article-title":"Sclareol-loaded hyaluronan-coated PLGA nanoparticles: Physico-chemical properties and in vitro anticancer features","volume":"132","author":"Cosco","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.intimp.2023.110214_b0600","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3109\/03639045.2014.902465","article-title":"Co-administration with cell penetrating peptide enhances the oral bioavailability of docetaxel-loaded nanoparticles","volume":"41","author":"Bu","year":"2015","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.intimp.2023.110214_b0605","doi-asserted-by":"crossref","unstructured":"A. Razak SA, Mohd Gazzali A, Fisol FA, M. Abdulbaqi I, Parumasivam T, Mohtar N, A. Wahab H. Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: An overview. Cancers, 2021; 13: 400.","DOI":"10.3390\/cancers13030400"},{"key":"10.1016\/j.intimp.2023.110214_b0610","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3109\/03639045.2012.694588","article-title":"Sulfobutylether-\u03b2-cyclodextrin\/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel","volume":"39","author":"Wu","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.intimp.2023.110214_b0615","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jconrel.2015.04.020","article-title":"Manganese oxide and docetaxel co-loaded fluorescent polymer nanoparticles for dual modal imaging and chemotherapy of breast cancer","volume":"209","author":"Abbasi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2023.110214_b0620","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2147\/IJN.S121881","article-title":"Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile","volume":"12","author":"Rafiei","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.intimp.2023.110214_b0625","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/chrsci\/49.2.136","article-title":"Application of validated RP-HPLC method for simultaneous determination of docetaxel and ketoconazole in solid lipid nanoparticles","volume":"49","author":"Venishetty","year":"2011","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.intimp.2023.110214_b0630","doi-asserted-by":"crossref","unstructured":"S.M. Kong, D.F. Costa, A. Jagielska, K.J. Van Vliet, P.T. Hammond, Stiffness of targeted layer-by-layer nanoparticles impacts elimination half-life, tumor accumulation, and tumor penetration, Proc. Natl. Acad. Sci., 2021; 118: e2104826118.","DOI":"10.1073\/pnas.2104826118"},{"key":"10.1016\/j.intimp.2023.110214_b0635","first-page":"1973","article-title":"The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment","volume":"6","author":"Yang","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.intimp.2023.110214_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.117187","article-title":"Chondroitin sulfate-hybridized zein nanoparticles for tumor-targeted delivery of docetaxel","volume":"253","author":"Lee","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.intimp.2023.110214_b0645","first-page":"5249","article-title":"Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells","volume":"10","author":"Tran","year":"2015","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.intimp.2023.110214_b0650","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.scib.2018.12.025","article-title":"Tumor microenvironment-responsive docetaxel-loaded micelle combats metastatic breast cancer","volume":"64","author":"Lang","year":"2019","journal-title":"Science Bulletin"},{"key":"10.1016\/j.intimp.2023.110214_b0655","first-page":"1903","article-title":"Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies","volume":"6","author":"Koopaei","year":"2011","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.intimp.2023.110214_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2019.04.006","article-title":"Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides","volume":"20","author":"Sorolla","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.intimp.2023.110214_b0665","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2015.11.029","article-title":"Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition","volume":"221","author":"Jiang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2023.110214_b0670","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.actbio.2018.07.021","article-title":"Tumor microenvironment-labile polymer\u2013doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma","volume":"77","author":"Zhang","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.intimp.2023.110214_b0675","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijpharm.2014.05.021","article-title":"Docetaxel\u2013carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer","volume":"471","author":"Hoang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.intimp.2023.110214_b0680","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.biomaterials.2011.06.028","article-title":"Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic\u00ae for tumor-targeted delivery of docetaxel","volume":"32","author":"Cho","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2023.110214_b0685","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1016\/j.biomaterials.2012.02.019","article-title":"Tumor-targeted drug delivery using MR-contrasted docetaxel \u2013 Carboxymethylcellulose nanoparticles","volume":"33","author":"Ernsting","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2023.110214_b0690","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12951-020-00604-7","article-title":"Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells","volume":"18","author":"da Rocha","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.intimp.2023.110214_b0695","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2015.06.017","article-title":"Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer","volume":"64","author":"Xu","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2023.110214_b0700","doi-asserted-by":"crossref","first-page":"128ra39","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.intimp.2023.110214_b0705","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-5514","article-title":"Abstract 5514: Pharmacokinetics of BIND-014 (docetaxel nanoparticles for injectable suspension) in preclinical species and patients with advanced solid tumors","volume":"75","author":"Summa","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2023.110214_b0710","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-15-2548","article-title":"Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors","volume":"22","author":"Von Hoff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110214_b0715","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","article-title":"Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial","volume":"4","author":"Autio","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0720","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2016.34.2_suppl.233","article-title":"A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer (mCRPC)","volume":"34","author":"Autio","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.110214_b0725","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-20-0008","article-title":"Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors","volume":"26","author":"Atrafi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110214_b0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-01186-8","article-title":"A novel targeted multifunctional nanoplatform for visual chemo-hyperthermia synergy therapy on metastatic lymph nodes via lymphatic delivery","volume":"19","author":"Liu","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.intimp.2023.110214_b0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11051-019-4580-8","article-title":"Docetaxel-loaded biomimetic nanoparticles for targeted lung cancer therapy in vivo","volume":"21","author":"Chi","year":"2019","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.intimp.2023.110214_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2019.100157","article-title":"Evaluation of cytotoxic activity of docetaxel loaded gold nanoparticles for lung cancer drug delivery","volume":"21","author":"Thambiraj","year":"2019","journal-title":"Cancer Treatment Res. Commun."},{"key":"10.1016\/j.intimp.2023.110214_b0745","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1021\/acsnano.2c01252","article-title":"Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with immune modulatory drugs","volume":"16","author":"Nel","year":"2022","journal-title":"ACS Nano"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923005350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923005350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:23:14Z","timestamp":1785770594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923005350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":149,"alternative-id":["S1567576923005350"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110214","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interactions of docetaxel with tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110214"}}